Sandbox:Maneesha: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign or Malignant
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign
! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestation
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant
! colspan="9" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestation
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Paraclinical findings
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Paraclinical findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard diagnosis
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard diagnosis
Line 16: Line 14:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Signs
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab findings
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab findings
Line 22: Line 20:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
Line 32: Line 29:
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congenital
! colspan="2" align="center" style="background:#DCDCDC;" |Branchial cleft cyst
! colspan="2" align="center" style="background:#DCDCDC;" |Branchial cleft cyst
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Benign
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 51: Line 45:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Thyroglossal duct cyst
! colspan="2" align="center" style="background:#DCDCDC;" |Thyroglossal duct cyst
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 70: Line 61:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Hemangioma
! colspan="2" align="center" style="background:#DCDCDC;" |Hemangioma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 89: Line 77:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Vascular malformations
! colspan="2" align="center" style="background:#DCDCDC;" |Vascular malformations
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 108: Line 93:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Lymphatic malformations
! colspan="2" align="center" style="background:#DCDCDC;" |Lymphatic malformations
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 127: Line 109:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Laryngocele
! colspan="2" align="center" style="background:#DCDCDC;" |Laryngocele
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 146: Line 125:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Ranula
! colspan="2" align="center" style="background:#DCDCDC;" |Ranula
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 165: Line 141:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Teratoma
! colspan="2" align="center" style="background:#DCDCDC;" |Teratoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 184: Line 157:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Dermoid cyst
! colspan="2" align="center" style="background:#DCDCDC;" |Dermoid cyst
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 203: Line 173:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Thymic cyst
! colspan="2" align="center" style="background:#DCDCDC;" |Thymic cyst
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 223: Line 190:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
Line 243: Line 207:
| rowspan="21" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammatory
| rowspan="21" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammatory
! colspan="2" align="center" style="background:#DCDCDC;" |Acute sialadenitis
! colspan="2" align="center" style="background:#DCDCDC;" |Acute sialadenitis
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 262: Line 223:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Chronic sialadenitis
! colspan="2" align="center" style="background:#DCDCDC;" |Chronic sialadenitis
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 282: Line 240:
! rowspan="4" align="center" style="background:#DCDCDC;" |Reactive viral lymphadenopathy
! rowspan="4" align="center" style="background:#DCDCDC;" |Reactive viral lymphadenopathy
! align="center" style="background:#DCDCDC;" |CMV
! align="center" style="background:#DCDCDC;" |CMV
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 301: Line 256:
|-
|-
! align="center" style="background:#DCDCDC;" |EBV
! align="center" style="background:#DCDCDC;" |EBV
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 320: Line 272:
|-
|-
! align="center" style="background:#DCDCDC;" |HIV
! align="center" style="background:#DCDCDC;" |HIV
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 339: Line 288:
|-
|-
! align="center" style="background:#DCDCDC;" |Viral URI
! align="center" style="background:#DCDCDC;" |Viral URI
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 359: Line 305:
! rowspan="6" align="center" style="background:#DCDCDC;" |Bacterial lymphadenopathy
! rowspan="6" align="center" style="background:#DCDCDC;" |Bacterial lymphadenopathy
! align="center" style="background:#DCDCDC;" |Tularemia
! align="center" style="background:#DCDCDC;" |Tularemia
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 378: Line 321:
|-
|-
! align="center" style="background:#DCDCDC;" |Brucellosis
! align="center" style="background:#DCDCDC;" |Brucellosis
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 397: Line 337:
|-
|-
! align="center" style="background:#DCDCDC;" |Cat-scratch disease
! align="center" style="background:#DCDCDC;" |Cat-scratch disease
| align="center" style="background:#F5F5F5;" |
:* ''Bartonella henselae'' infection
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 417: Line 353:
|-
|-
! align="center" style="background:#DCDCDC;" |Actinomycosis  
! align="center" style="background:#DCDCDC;" |Actinomycosis  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 436: Line 369:
|-
|-
! align="center" style="background:#DCDCDC;" |Mycobacterial infections  
! align="center" style="background:#DCDCDC;" |Mycobacterial infections  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 455: Line 385:
|-
|-
! align="center" style="background:#DCDCDC;" |Staphylococcal or streptococcal infection
! align="center" style="background:#DCDCDC;" |Staphylococcal or streptococcal infection
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 475: Line 402:
! align="center" style="background:#DCDCDC;" |Parasitic lymphadenopathy
! align="center" style="background:#DCDCDC;" |Parasitic lymphadenopathy
! align="center" style="background:#DCDCDC;" |Toxoplasma gondii
! align="center" style="background:#DCDCDC;" |Toxoplasma gondii
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 494: Line 418:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Sarcoidosis
! colspan="2" align="center" style="background:#DCDCDC;" |Sarcoidosis
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 513: Line 434:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Amyloidosis
! colspan="2" align="center" style="background:#DCDCDC;" |Amyloidosis
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 532: Line 450:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Sjögren syndrome
! colspan="2" align="center" style="background:#DCDCDC;" |Sjögren syndrome
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 551: Line 466:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Castleman disease (angiofollicular lymphoproliferative disease)
! colspan="2" align="center" style="background:#DCDCDC;" |Castleman disease (angiofollicular lymphoproliferative disease)
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 570: Line 482:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Kikuchi disease (histiocytic necrotizing lymphadenitis)
! colspan="2" align="center" style="background:#DCDCDC;" |Kikuchi disease (histiocytic necrotizing lymphadenitis)
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 589: Line 498:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Kimura disease
! colspan="2" align="center" style="background:#DCDCDC;" |Kimura disease
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 608: Line 514:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Rosai-Dorfman disease
! colspan="2" align="center" style="background:#DCDCDC;" |Rosai-Dorfman disease
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 627: Line 530:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Kawasaki disease
! colspan="2" align="center" style="background:#DCDCDC;" |Kawasaki disease
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 647: Line 547:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
Line 667: Line 564:
! rowspan="20" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Neoplasm
! rowspan="20" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Neoplasm
! colspan="2" align="center" style="background:#DCDCDC;" |Primary thyroid tumor
! colspan="2" align="center" style="background:#DCDCDC;" |Primary thyroid tumor
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 687: Line 581:
! rowspan="10" align="center" style="background:#DCDCDC;" |Salivary gland neoplasm
! rowspan="10" align="center" style="background:#DCDCDC;" |Salivary gland neoplasm
! align="center" style="background:#DCDCDC;" |Pleomorphic adenoma
! align="center" style="background:#DCDCDC;" |Pleomorphic adenoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 706: Line 597:
|-
|-
! align="center" style="background:#DCDCDC;" |Warthin's tumor
! align="center" style="background:#DCDCDC;" |Warthin's tumor
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 725: Line 613:
|-
|-
! align="center" style="background:#DCDCDC;" |Lymphoepithelioma
! align="center" style="background:#DCDCDC;" |Lymphoepithelioma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 744: Line 629:
|-
|-
! align="center" style="background:#DCDCDC;" |Oncocytoma
! align="center" style="background:#DCDCDC;" |Oncocytoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 763: Line 645:
|-
|-
! align="center" style="background:#DCDCDC;" |Monomorphic adenoma
! align="center" style="background:#DCDCDC;" |Monomorphic adenoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 782: Line 661:
|-
|-
! align="center" style="background:#DCDCDC;" |Mucoepidermoid carcinoma
! align="center" style="background:#DCDCDC;" |Mucoepidermoid carcinoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 801: Line 677:
|-
|-
! align="center" style="background:#DCDCDC;" |Adenoid cystic carcinoma
! align="center" style="background:#DCDCDC;" |Adenoid cystic carcinoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 820: Line 693:
|-
|-
! align="center" style="background:#DCDCDC;" |Adenocarcinoma
! align="center" style="background:#DCDCDC;" |Adenocarcinoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 839: Line 709:
|-
|-
! align="center" style="background:#DCDCDC;" |Salivary duct carcinoma
! align="center" style="background:#DCDCDC;" |Salivary duct carcinoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 858: Line 725:
|-
|-
! align="center" style="background:#DCDCDC;" |Squamous cell carcinoma
! align="center" style="background:#DCDCDC;" |Squamous cell carcinoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 877: Line 741:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Parathyroid tumors
! colspan="2" align="center" style="background:#DCDCDC;" |Parathyroid tumors
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 896: Line 757:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Carotid body tumors
! colspan="2" align="center" style="background:#DCDCDC;" |Carotid body tumors
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 915: Line 773:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Paraganglioma
! colspan="2" align="center" style="background:#DCDCDC;" |Paraganglioma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 934: Line 789:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Schwannoma
! colspan="2" align="center" style="background:#DCDCDC;" |Schwannoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 953: Line 805:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Lymphoma
! colspan="2" align="center" style="background:#DCDCDC;" |Lymphoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 972: Line 821:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Liposarcoma
! colspan="2" align="center" style="background:#DCDCDC;" |Liposarcoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 991: Line 837:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Lipoma  
! colspan="2" align="center" style="background:#DCDCDC;" |Lipoma  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,010: Line 853:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Glomus vagale, glomus jugulare tumors
! colspan="2" align="center" style="background:#DCDCDC;" |Glomus vagale, glomus jugulare tumors
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,029: Line 869:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Metastatic head and neck carcinoma
! colspan="2" align="center" style="background:#DCDCDC;" |Metastatic head and neck carcinoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,049: Line 886:
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="2" align="center" style="background:#DCDCDC;" |Hematoma
! colspan="2" align="center" style="background:#DCDCDC;" |Hematoma
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,068: Line 902:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Arteriovenous fistula
! colspan="2" align="center" style="background:#DCDCDC;" |Arteriovenous fistula
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,087: Line 918:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |Goiter
! colspan="2" align="center" style="background:#DCDCDC;" |Goiter
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 1,107: Line 935:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Demography
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |History
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mass
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pain
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Dysphagia

Revision as of 19:42, 23 January 2019


Differential diagnosis of neck masses

Differential diagnosis of neck masses include:

Category Diseases Benign or Malignant Clinical manifestation Paraclinical findings Gold standard diagnosis Associated findings
Demography History Symptoms Signs Lab findings Histopathology Imaging
Pain Dysphagia Mass exam Skin changes LAP Others
Congenital Branchial cleft cyst Benign
Thyroglossal duct cyst
Hemangioma
Vascular malformations
Lymphatic malformations
Laryngocele
Ranula
Teratoma
Dermoid cyst
Thymic cyst
Category Diseases Benign Demography History Pain Dysphagia Mass exam Skin changes LAP Others Lab findings Histopathology Imaging Gold standard diagnosis Associated findings
Inflammatory Acute sialadenitis
Chronic sialadenitis
Reactive viral lymphadenopathy CMV
EBV
HIV
Viral URI
Bacterial lymphadenopathy Tularemia
Brucellosis
Cat-scratch disease
Actinomycosis
Mycobacterial infections
Staphylococcal or streptococcal infection
Parasitic lymphadenopathy Toxoplasma gondii
Sarcoidosis
Amyloidosis
Sjögren syndrome
Castleman disease (angiofollicular lymphoproliferative disease)
Kikuchi disease (histiocytic necrotizing lymphadenitis)
Kimura disease
Rosai-Dorfman disease
Kawasaki disease
Category Diseases Benign Demography History Pain Dysphagia Mass exam Skin changes LAP Others Lab findings Histopathology Imaging Gold standard diagnosis Associated findings
Neoplasm Primary thyroid tumor
Salivary gland neoplasm Pleomorphic adenoma +
Warthin's tumor +
Lymphoepithelioma +
Oncocytoma
Monomorphic adenoma
Mucoepidermoid carcinoma
Adenoid cystic carcinoma
Adenocarcinoma
Salivary duct carcinoma
Squamous cell carcinoma
Parathyroid tumors
Carotid body tumors
Paraganglioma
Schwannoma
Lymphoma
Liposarcoma
Lipoma
Glomus vagale, glomus jugulare tumors
Metastatic head and neck carcinoma
Other Hematoma
Arteriovenous fistula
Goiter
Category Diseases Benign Demography History Pain Dysphagia Mass exam Skin changes LAP Others Lab findings Histopathology Imaging Gold standard diagnosis Associated findings

References